Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Imaging Biometrics AI Sinks 10% as Traders Take a Harder Look at the Healthcare-AI Story

The London-listed stock trading under the ticker LSE:IBAI is one of the market's smallest and most thinly traded healthcare names, and on 5-6 August 2026 it earned a place on London South East's "All-Share Fallers" list. According to that data, the shares closed at …

Divya Sood | 06 August 2026

Poolbeg Pharma Soars 15% — Is the Biotech Minnow Finally Entering a New Growth Phase?

Shares in the AIM-listed clinical-stage group ended Wednesday 5 August 2026 at 8.00p, a rise of 1.10p, or 15.28%, on the day, according to London South East's All-Share risers list. It was one of the steeper single-session gains on the junior market, and it …

Divya Sood | 06 August 2026

LSE:CRTX Jumps 5.26% on Growing Optimism Around CRISM Therapeutics' Cancer Pipeline

LSE:CRTXgained5.26% on 6 August 2026as buying interest returned to the healthcare sector, with investors focusing on companies approaching important clinical development milestones.

Ankur Sharma | 06 August 2026

Can LSE:VAL Continue Its Rally? ValiRx Attracts Fresh Buying Interest Amid Healthcare Momentum

LSE:VALadvanced4.91% on 6 August 2026as investors returned to selected biotechnology companies with differentiated oncology development strategies and multiple potential commercial catalysts.

Ankur Sharma | 06 August 2026

Why Is LSE:ABDX in Focus Today? Abingdon Health Benefits from Expanding Point-of-Care Testing Market

LSE:ABDXadvanced4.67% on 6 August 2026as investors showed renewed interest in healthcare technology companies benefiting from increasing demand for rapid diagnostic solutions and contract development services.

Ankur Sharma | 06 August 2026

Why Did LSE:FUM Shares Rise More Than 5% Today? Futura Medical Gains as Commercial Growth Story Builds

Futura Medical plc attracted renewed buying interest during Thursday's trading session afterLSE:FUM advanced 5.54%, outperforming many healthcare peers on the UK market.

Ankur Sharma | 06 August 2026

AstraZeneca's (LSE:AZN) $400bn Mega-Merger Talks Could Redraw the Global Pharmaceutical Industry

Reports of a tie-up between Britain's most valuable company and its US rival remain unconfirmed by either side, with no deal terms in existence. The "$400bn" is combined market value, not a transaction price, and scepticism is warranted.

Ankur Sharma | 06 August 2026

The £400bn Gamble: Why AstraZeneca (LSE:AZN) Investors Are Nervous About a Bristol Myers Deal

A Financial Times report of preliminary AstraZeneca–Bristol Myers Squibb talks — unconfirmed by either company — knocked up to 9% off AstraZeneca's shares. Note the headline's "£400bn" is a sterling overstatement: the combined value is roughly $400bn, about £315bn.

Ankur Sharma | 06 August 2026

Shield Therapeutics Plc (LSE:STX) Extends Green Momentum as ACCRUFeR Growth and Clinical Progress Strengthen Investor Confidence

Shield Therapeutics Plc is a commercial-stage pharmaceutical company focused on the treatment of iron deficiency through its flagship therapy,ACCRUFeR®(ferric maltol). The company markets its treatment across multiple international markets while pursuing additional regulatory approvals, label expansions, and commercial partnerships to broaden its global reach.

Ankur Sharma | 06 August 2026

Renalytix Plc (LSE:RENX) Gains Strong Upward Momentum as AI-Driven Kidney Diagnostics Fuel Investor Optimism

Renalytix Plc is a precision medicine company specializing in artificial intelligence-enabled diagnostics for chronic kidney disease. Its flagship product,KidneyIntelX.dkd, is an FDA-authorized prognostic test designed to identify patients at elevated risk of kidney disease progression, enabling earlier clinical intervention and improved patient outcomes.

Ankur Sharma | 06 August 2026
Support

Hi! How can we help you today?

Loading…